Is Eli Lilly Co. a Buy?

PUBLISHED Jul 2, 2024, 1:54:27 PM        SHARE

img
imgNoah Brody

Is Eli Lilly and Company a Buy?

About Eli Lilly (LLY)

Eli Lilly and Company are an American pharmaceutical company founded in 1876, and headquartered in Indianapolis, Indiana. Their focus has been on the development and research of medications and therapies to treat depression, such as Prozac and Cymbalta, as well as their drugs for diabetes, Humalog and Trulicity. These combine to bring in the majority of Eli Lilly’s revenues, which in 2023 was over $34 billion.

The increase in their revenues has been consistent, and is one of the reasons that Eli Lilly is one of the largest healthcare companies in the world, ranking 127th in the Fortune 500. This is a large factor in the increase in stock price, which at the time of this writing is $893.98. This is one of the higher stock prices in the sector, and does potentially raise red flags for investors.

The formula to determine intrinsic value by GuruFocus, which I have written about in previous articles, is not kind to Eli Lilly. Their formula places an intrinsic value of $57.07, far lower than the current price. This is worse than 96% of other companies in the drug manufacturing sector. While this is certainly not good, there are other factors in play when determining the value of Eli Lilly’s stock.

The dividend for Eli Lilly has been a mixed bag. Over the past 20 years, they have never decreased their dividend, but also have not increased every year. Notably, from 2009-2014, they did not increase their quarterly dividend of $0.49. Currently, Eli Lilly pays annual dividends of 0.59% which is certainly not as strong as I would hope. The quarterly dividend of $1.30 comes after two years of the largest dividend increases in the company’s history, so there is potential in the future for this to become a strength.

What I Thought of Eli Lilly’s Q1 Earnings Report

Eli Lilly’s Q1 earnings for 2024 were certainly optimistic, as they improved over last year’s Q1 revenue by 26%. This is tremendous growth, and in addition to higher revenue, they also returned greater earnings per share versus last year, coming in 66% greater than last year. These are strong signs, and have contributed to YTD increases in their stock price of nearly 50%. It has been an incredible year for investors in LLY, but is the time to buy already behind us?

Based on the projections for their revenue for the remainder of the year, there is still significant potential for greater increases to their stock price. Much of this success can be attributed to the increase in sales for Mounjaro. Mounjaro is a diabetes medication, similar to Ozempic, that has also shown signs of assisting in weight loss. It is important to note that Eli Lilly has NOT encouraged use of Mounjaro for cosmetic weight loss, though there is reason to believe that weight loss has been a factor for some using the medication.

Risk and Uncertainty?

One potential cause for concern for those considering investing in Eli Lilly is the number of shares being bought versus those being sold. According to Stockinvest.us, over 100 transactions, 6.36 thousand shares were bought, but in the same time 1.13 million were sold. Others, however, are saying they can see the stock price reaching $1,000 per share as Eli Lilly seeks to become the first healthcare company with a market cap over $1 trillion.

A large amount of uncertainty, but also optimism, is on the horizon. The development of a new Alzheimer’s treatment drug offers tremendous potential, as advisors to the FDA have endorsed the new medication. This new medication, Donanemab, is intended to slow the progression of Alzheimers in patients, but has already once been denied FDA approval while they ran more trials to determine its safety and viability.

If Donanemab is granted FDA approval this year, it could provide tremendous additional revenue to Eli Lilly, as competing medications can cost up to $26,000 annually. This does hinge on eventual FDA approval, which is not a guarantee, and anything less could negatively impact the stock price. We have seen in other companies that drugs that do not gain FDA approval can have adverse impacts to stock price.

Is Eli Lilly a Buy or Sell Opportunity?

There is some uncertainty in the prospects of investing in Eli Lilly, but while there is some risk, many are still saying Eli Lilly is a buy opportunity. Investors.com says the optimism for Donanemab is leading to the stock trading at all-time highs, and is even still a strong opportunity for investors. This seems to be the consensus among many investors, as all signs appear to point towards continued increases to the stock price, as well as increasing revenues in the next few years.

Eli Lilly appears on track to become the first healthcare stock to reach a market cap of $1 trillion, while also having the potential to reach $1,000 per share. Some analysts have set their price targets as high as $1,000 due to the success of their diabetes and weight-loss medications, as well as the potential benefits of Donanemab as soon as the end of this year.

All this combines to indicate that the market may be right, and that Eli Lilly should be considered a buy, as there is too much positive momentum and uninterrupted stock growth to be ignored. Eli Lilly appears poised to continue surpassing its competitors, and will likely become the first healthcare company with a $1 trillion market cap.



Sound investments
don't happen alone

Find your crew, build teams, compete in VS MODE, and identify investment trends in our evergrowing investment ecosystem. You aren't on an island anymore, and our community is here to help you make informed decisions in a complex world.

More Reads
Is AbbVie Stock a Buy?
Image

AbbVie is one of the largest pharmaceutical companies in the world, but should you buy?

CVS Health (Aetna Inc.) vs Cigna Group
Image

Which health insurance company is a better buy opportunity?

Expecting A Dip
Image

Stock Market Commentary

Differentiators
Image

How Stockbossup is different

If anyone listened they got a huge gain
Image

I have a post for 8/20/2022

Is Healthcare a Good Investment Right Now?
Image

Taking a deep dive into the healthcare sector to determine if it is a good time to buy!

Medtronic Vs Stryker: Which is a Better Buy?
Image

Which of these two major players in the medical device sector is a better buy?

What Materials Should I Invest in?
Image

The materials sector has a wide range of options for different investment strategies. From the speculative nature of rare earth elements to the income strategies around timber production, an investor looking through material stocks has a lot of directions to go.

What will the Metaverse be in five years?
Image

The metaverse is here to stay as the next iteration of the internet. While an older generation may not see why this is the next technology, a younger generation and their parents are seeing the transition.

Virtual Events in the Metaverse
Image

People are more than ever going to live events, but virtual events are seeing an uptick in 2024. With new ad revenue streams in works, virtual events could see a new resurgence.

Metaverse ETFs
Image

While the Metaverse megatrend is looking promising in 2024, the collapse in metaverse investments prices in 2021 and 2022 caused at least three metaverse themed ETFs to liquidate.

Microsoft and the Growth Explosion
Image

Microsoft is an amazing stock for new investors to try. The company has evolved, acquired, and developed a multifaceted set of businesses that are fundamentally driving growth. But for new investors, the barrier to entry is mindset.

AGCO Group - The Pure-Play Farming Stock May be too Hot!
Image

The stock’s intrinsic value clearly shows the cyclicality of the farming industry, independent of AGCO’s own analysis. Agco’s analysis also takes into account the farming industry cyclicality.

Littelfuse - Undervalued Opportunity to Hold for Years
Image

Littelfuse (LFUS) is a component manufacturer currently near a $6 Billion market capitalization. This makes it a small-cap stock, with the potential for further growth in its market segments or to be bought out by a competitor.

Dover Corporation - Great Dividend Stock but Possibly Overpriced
Image

Dover Corporation is a strong investment candidate thanks to its consistent dividend growth, its robust financial performance, and strong capital implementation plan. This stock fits into a strong dividend portfolio well that plans on holding onto stocks for multiple years.

Is BorgWarner a Buy?
Image

BorgWarner fell below $30 today, making it an interesting buy opportunity. The reasons are quite straightforward. The company’s book value per share is $25.36 a share. This means that as long as money continues to be made, BorgWarner becomes undervalued if it nears its book value per share.

Union Pacific is Going Nowhere
Image

Union Pacific is not a buy to start off 2024. Union Pacific is a fine business. There are issues but nothing that is significant enough to believe the company’s intrinsic value will shrink in the next decade.

Dividend Stock Watch List: Lanny’s February 2024 Edition
Image

Dividend investing happens, whether the stock market is up or down, whether the fed raises interest rates or lowers. Inflation or deflation. Banks are failing or being bailed out. Recession, no recession. It’s all about buying dividend income producing stocks – the best source of passive income source on your journey to financial freedom!

January 2024 Stock Considerations
Image

With a new trading year already in full swing it is time, once again, to highlight some of my potential stock purchases for the month.

5 Reasons Not to Use ChatGPT for Financial Advice
Image

It’s truly amazing how far AI has come in such a short period. Not only can it answer most questions, but it can also generate online posts, research papers, and even poetry. However, it still has its limitations.

Resources for Publishers
Resources for New Investors
Boosted with BossCoin
Financial Literacy Leaders
user_profile
Tom Hamilton
user_profile
Wise Intelligent
user_profile
Mark Robertson
user_profile
Kevin Matthews II
user_profile
Akeiva Ellis
user_profile
Brendan Dale
user_profile
Kenneth Chavis IV
user_profile
Sharita Humphrey